Inhaled small-molecule mucolytic drug for COPD
| Date | Round | Amount |
|---|---|---|
| Apr 2023 | Series A Irish-founded biopharma Aer Therapeutics (US-headquartered) closed a $36m Series A to advance its inhaled COPD mucolytic drug AER-01. | $36M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.